Upcoming Presentations by BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) is gearing up for an exciting series of investor conferences that highlight their innovative work in biotechnology. With a mission to improve the lives of individuals battling hereditary angioedema and other rare diseases, the company is poised to share its progress and insights at multiple upcoming events.
Details of the Investor Conferences
BioCryst Pharmaceuticals will present at several notable conferences in the near future. These conferences provide an excellent platform for the company to discuss its innovations and engage with the investment community. Here are the specifics of the conferences:
Jefferies London Healthcare Conference
The first on the agenda is the 2024 Jefferies London Healthcare Conference. This significant event will take place on November 20, 2024, allowing BioCryst to showcase its advancements and vision. The presentation is scheduled for 5:00 a.m. ET, where attendees can learn more about the company's strategic direction.
Evercore HealthCONx Conference
Following the London event, BioCryst will participate in the 7th Annual Evercore HealthCONx Conference in Coral Gables. This presentation is set for December 4, 2024, at 2:35 p.m. ET, and it’s another great opportunity for the company to engage with key stakeholders in the healthcare industry.
Piper Sandler Healthcare Conference
Finally, the company will be making its way to New York for the Piper Sandler 36th Annual Healthcare Conference. Scheduled for December 5, 2024, at 8:30 a.m. ET, this event marks an important occasion for BioCryst to discuss its progress in developing groundbreaking therapeutics.
Accessing Live Presentations
For those interested in following these presentations, BioCryst will provide access to live audio webcasts and replay options. The details for these audio broadcasts will be available in the Investors & Media section of the BioCryst website, thus allowing stakeholders to stay informed about the company's latest updates and accomplishments.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a distinguished player in the biotechnology sector. With a strong focus on rare diseases, the company employs its expertise in structure-guided drug design to innovate and develop therapies. BioCryst’s notable product, ORLADEYO (berotralstat), represents a significant advancement as the first oral, once-daily plasma kallikrein inhibitor. The company continues to develop a robust pipeline of both small-molecule and protein therapies aimed at tackling challenging medical conditions.
Contact Information
For any inquiries or further information, representatives from BioCryst are more than willing to assist. Contact John Bluth at +1 919 859 7910, or reach out via email at jbluth@biocryst.com.
Frequently Asked Questions
What is BioCryst Pharmaceuticals known for?
BioCryst Pharmaceuticals is recognized for its focus on developing innovative therapies, especially for rare diseases such as hereditary angioedema.
When will BioCryst present at the Jefferies Conference?
BioCryst will present at the Jefferies London Healthcare Conference on November 20, 2024, at 5:00 a.m. ET.
Where can I find more information about the presentations?
Details about the live audio webcasts and presentation replays will be available in the Investors & Media section on BioCryst's official website.
What notable products has BioCryst developed?
One of BioCryst’s significant achievements is ORLADEYO (berotralstat), which is the first oral, once-daily plasma kallikrein inhibitor.
How can I contact BioCryst Pharmaceuticals for more details?
You can contact John Bluth at +1 919 859 7910 or via email at jbluth@biocryst.com for additional information.
